The company plans to recruit one million patients from Mexico over three years and then expand to Columbia, Argentina, and Brazil.
The Norwegian microbiome-focused clinical diagnostics company has ceded commercialization rights in certain undisclosed territories to Bio-Rad as part of the deal.
The effort aims to identify a suite of markers that could aid in management of type II diabetes and related conditions like retinopathy and kidney damage.
The companies will use Myriad RBM's CustomMAP platform to measure cardiovascular risk biomarkers in patients treated with a Sanofi diabetes drug.
Researchers uncovered 60 genomic loci associated with birth weight and found that those regions are also linked to risk for type 2 diabetes and other diseases.
Researchers saw both short- and long-term changes in metabolite profiles in blood plasma from individuals who'd undergone Roux-en-Y gastric bypass surgery.
The core technology uses proximity-ligated amplification and the firm will build it into tests for type I diabetes as well as highly multiplexed assays.
A genome-wide association and fine-mapping study of Samoans led to a missense mutation in the CREBRF gene that seems to correspond with increased fat storage.
The company plans to launch the 12-protein panel as a CLIA test for longitudinal monitoring of cardiovascular disease, kidney disease, and diabetes.
A Winthrop-University Hospital team showed that demethylated circulating cell-free DNA from dying oligodendrocytes is a biomarker for relapsing-remitting MS.
In the study, the partners will perform exome sequencing and whole-genome array genotyping on more than 9,000 individuals with diabetes or with diabetic relatives.
The portal offers access to genotype, phenotype, and clinical data related to type 2 diabetes as well as computational tools for querying the information.
The addition of certain kinds of information could help clinical labs determine whether variants of uncertain significance are pathogenic or benign.
Researchers diagnosed almost 70 percent of the neurometabolic cases they tackled, using exome sequence data for dozens of affected children and their families.
The funding will support development of tests that detect cell-free DNA methylation patterns indicative of disease in specific tissues of the body.
CeMeT, short for Center for Metagenomics, was founded in 2014 as a spinout from genetic diagnostics firm CeGaT in Tübingen.
The WUSTL-developed method detects a bile acid that is found at increased levels in Niemann-Pick patients, and is ready for pilot testing, its developers said.
Scientists from the Okinawa Institute of Science and Technology and Kyoto University have found 14 metabolites whose levels differ in older individuals' blood.
Initially studying pancreatic tissue, the team also linked their findings to methylation patterns in blood, suggesting the possibility of developing a non-invasive test.
Metabolon's test, called Quantose IR, uses insulin and three non-glycemic biomarkers to assess the risk of a patient becoming prediabetic.
The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.
Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.
CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.
In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.